Metoprolol Succinate Amlodipine Tablet

ROOTOPINE-M

Metoprolol Succinate Prolonged Release 25 mg and Amlodipine 5 mg Tablets

Division: DIABGLYM

Composition

Each prolonged-release tablet contains:

Metoprolol Succinate PR IP — 25 mg

Amlodipine Besylate IP equivalent to Amlodipine — 5 mg

Excipients — q.s.

Colour: Approved colour used

Dosage form: Prolonged-release oral tablet

Product Description

ROOTOPINE-M is a once-daily antihypertensive combination of Metoprolol Succinate Prolonged Release 25 mg and Amlodipine 5 mg, formulated for the effective management of hypertension, chronic stable angina, coronary artery disease, and long-term cardiovascular risk reduction. This combination provides sustained 24-hour blood pressure control by combining the prolonged beta-blocking action of Metoprolol Succinate with the long-acting vasodilatory effect of Amlodipine.

Metoprolol Succinate PR is a cardioselective beta-1 adrenergic receptor blocker that provides controlled drug release throughout the day, helping maintain stable plasma concentrations, reduce heart rate, decrease myocardial oxygen demand, and improve cardiovascular outcomes. Amlodipine is a long-acting calcium channel blocker that relaxes vascular smooth muscle, reduces peripheral vascular resistance, and improves coronary blood flow.

ROOTOPINE-M is particularly beneficial in patients with hypertension associated with tachycardia, ischemic heart disease, diabetes mellitus, metabolic syndrome, left ventricular dysfunction, and high cardiovascular risk. The prolonged-release formulation enhances patient compliance through convenient once-daily dosing and consistent blood pressure control.

Technical Knowledge of Metoprolol Succinate PR and Amlodipine

Metoprolol Succinate PR selectively blocks beta-1 adrenergic receptors in the heart, reducing sympathetic stimulation, heart rate, myocardial contractility, and renin secretion from the kidneys. The prolonged-release formulation provides sustained therapeutic activity and minimizes fluctuations in drug concentration.

Amlodipine inhibits L-type calcium channels in vascular smooth muscle, producing peripheral arterial vasodilation, reduced systemic vascular resistance, decreased afterload, and improved coronary perfusion. It has a long elimination half-life, making it highly effective for once-daily antihypertensive therapy.

The combination of Metoprolol Succinate PR and Amlodipine provides complementary mechanisms that improve blood pressure control, reduce myocardial oxygen demand, and provide comprehensive cardiovascular protection.

Mechanism of Action

Metoprolol Succinate PR reduces heart rate, decreases myocardial contractility, lowers cardiac output, suppresses renin release, and reduces myocardial oxygen demand through sustained beta-1 receptor blockade.

Amlodipine relaxes vascular smooth muscle, reduces peripheral vascular resistance, lowers afterload, improves coronary blood flow, and provides long-lasting antihypertensive action.

Key Benefits

Sustained 24-hour blood pressure control

Once-daily prolonged-release therapy

Reduces heart rate and myocardial workload

Improves coronary blood flow

Helps control chronic stable angina

Reduces cardiovascular morbidity and mortality

Enhances patient compliance

Provides long-term cardiovascular protection

Suitable for sustained hypertension management under medical supervision

Clinical Applications

ROOTOPINE-M is commonly prescribed for essential hypertension, hypertension with tachycardia, chronic stable angina, coronary artery disease, hypertension with diabetes, hypertension with metabolic syndrome, left ventricular dysfunction, and long-term cardiovascular risk reduction.

Facts About Metoprolol Succinate PR and Amlodipine

Metoprolol Succinate PR is a long-acting beta-blocker designed for once-daily administration and has extensive evidence supporting its use in hypertension, angina, and heart failure. Amlodipine is one of the most widely prescribed calcium channel blockers due to its excellent efficacy, long duration of action, and favorable tolerability profile. The combination is highly effective for patients requiring both heart rate control and sustained blood pressure reduction.

Key Facts

Once-daily prolonged-release antihypertensive therapy

Beta-blocker and calcium channel blocker combination

Provides sustained 24-hour blood pressure control

Effective in hypertension and chronic stable angina

Reduces cardiac workload and vascular resistance

Evidence-based cardiovascular combination therapy

Quality-assured pharmaceutical formulation

PCD Pharma Franchise Opportunity

ROOTOPINE-M is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, coronary artery disease, diabetes, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.

Why Choose ROOTOPINE-M for PCD Pharma Franchise?

High prescription potential

Strong physician and cardiologist acceptance

Attractive monopoly franchise opportunity

Competitive pricing

Promotional support available

Visual aids and marketing inputs

Consistent product quality

Excellent repeat business potential

Third Party Manufacturing

Chemsroot Pharmaceutical offers Third Party Manufacturing of Metoprolol Succinate PR 25 mg and Amlodipine 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.

Our Third Party Manufacturing Services Include

Private label manufacturing

Contract manufacturing

Custom brand manufacturing

Loan license manufacturing

DCGI-compliant production

GMP-certified manufacturing

Batch manufacturing documentation

Product registration support

Customized packaging and artwork

Monopoly franchise packaging

Bulk manufacturing capability

Manufacturing Features

Pharmaceutical-grade raw materials

IP/BP/USP quality standards

In-process quality control

Finished product testing

Stability-oriented prolonged-release formulation

Controlled-release tablet manufacturing technology

Blister and Alu-Alu packaging options

ROOTOPINE-M from DIABGLYM combines sustained blood pressure control, effective heart rate reduction, comprehensive cardiovascular protection, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and evidence-based prolonged-release antihypertensive combination.